Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

Abstract: According to the inventive method of making gels, the main mixture comprising most of the ingredients with the exception of a fatty alcohol is mixed, using at least one in-line mixer, with the gelling post-mix comprising the fatty alcohol. The preferred process includes the mixing of the main mixture and the gelling post-mix just prior to either filling or storing the composition.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

Abstract: Solid oral dosage forms of testosterone and methods for the preparation thereof are disclosed and described. The solid oral dosage form may include a therapeutically effective amount of testosterone in a substantially solid polyethylene glycol carrier. Such a form has been found to alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance.

Abstract: According to the inventive method of making gels, the main mixture comprising most of the ingredients with the exception of a fatty alcohol is mixed, using at least one in-line mixer, with the gelling post-mix comprising the fatty alcohol. The preferred process includes the mixing of the main mixture and the gelling post-mix just prior to either filling or storing the composition.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.

Abstract: Liquid and/or gel laundry detergent compositions which snap back at the end of dispensing, thus eliminating or minimizing the dripping from the container. Employing a non-neutralized fatty acid to the total surfactant weight % ratio within a specific range, defined by the Snap Index equation, results in liquids and/or gels with the desired snap-back property.

Abstract: Gel detergent compositions which pile-up on a surface, upon dispensing, to minimize the spreading of the gel to a substantially larger area. The gels that can pile up are less messy to use and provide better stain removal, since more detergent is concentrated on the desired area of fabric (e.g., the spot). The composition comprises from about 10% to about 35% of a surfactant, from about 0.1 to about 5% of a non-neutralized fatty acid; from about 50 to about 85% of water; with the total of anionic surfactants selected from soap, linear alkyl benzene sulfonic acid, primary and secondary alkyl sulfates being more than 50% of total surfactant level.

Abstract: Methods for the prevention or amelioration of urinary incontinence are disclosed and described. One method includes the coadministration of an anticholinergic agent with either an SSRI, or an SNRI, or both.

Abstract: A sher-thinnig lamellar gel detergent composition, employing non-neutralized fatty acid in a specific amount, depending on the total surfactant level. The weight % ratio of non-neutralized fatty acid to the total surfactant within a specific range, defined by the Gelling Index equation, results in gels with the desired properties. The inventive product offers an advantage of laundry pre-treater and a detergent in a single product.

Abstract: According to the inventive method of making gels, the main mixture comprising most of the ingredients with the exception of a non-neutralized fatty acid or sulphonic acid, and/or other anionic surfactant acids is mixed, using at least one in-line static mixer, with the gelling post-mix comprising the non-neutralized fatty acid or sulphonic acid, or other anionic surfactant acids. The preferred process includes the mixing of the main mixture and the gelling post-mix just prior to either filling or storing the composition.